靶点- |
作用机制- |
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1952-09-29 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)
The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.
100 项与 Bridge Bioresearch Plc 相关的临床结果
0 项与 Bridge Bioresearch Plc 相关的专利(医药)
100 项与 Bridge Bioresearch Plc 相关的药物交易
100 项与 Bridge Bioresearch Plc 相关的转化医学